ClinicalTrials.gg
CompletedNCT00665366Updated Dec 2, 2013Results posted

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

A Phase 3 interventional study of Aripiprazole and Placebo in Bipolar Disorder Mania, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 73 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-02.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 39 studies testing aripiprazole in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Aripiprazole · Bipolar Disorder.

Enrollment
5th of 37
493 · median 48
Started
2008
with 3 others
Phase 3
16 of 39
none open now
Registered
32nd of 39
by date
Lead sponsor
13 of 39
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 39 studies testing aripiprazole in Bipolar Disorder, this one is the 5th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2008, is one of 16 in phase 3, and was the 32nd registered.

Bipolar Disorder

1,686 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 39 studies testing aripiprazole in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing aripiprazole in Bipolar Disorder as a file.
02

Study summary

The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.

03

Conditions studied

  • Bipolar Disorder Mania
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Clinical diagnosis of bipolar I disorder mania, manic or mixed episode, with or without psychotic features
  • Current ongoing lithium or valproate treatment with the possibility of benefiting, based on the investigator's clinical judgment, from adjunctive treatment with aripiprazole
  • Therapeutic serum levels of lithium or valproate and a Young Mania Rating Total Score of 16 or higher at screening and baseline
  • Participants taking current lithium or valproate treatment combined with antipsychotic medication other than aripiprazole are acceptable, provided that the other antipsychotic medication is washed out at least 3 days prior to the blood draw for therapeutic plasma levels of lithium and valproate determination. Long-acting antipsychotics must be washed out prior to entering the double-blind treatment.

Key exclusion criteria:

  • Women of who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of product
  • A diagnosis of delirium, dementia, amnesia or other cognitive disorder, or a psychotic disorder
  • Current diagnosis of delirium, dementia, a cognitive disorder (ie, amnesia), or a psychotic disorder (ie, schizophrenia or schizoaffective disorder)
  • Current diagnosis of bipolar II disorder, bipolar disorder not otherwise specified, or any other primary psychiatric disorder other than bipolar I disorder mania
  • Thyroid pathology
  • Demonstrated cocaine abuse or dependence within the past 3 months prior to screening.
  • History of neuroleptic malignant syndrome from antipsychotic agents
  • Manic symptoms that investigator considers to treatment
  • Previous nonresponsive (by investigator judgment) to aripiprazole for manic symptoms
  • Significant risk of suicide based on history, mental status exam, or investigator judgment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
493 participants (actual)

Study arms

  • Placebo comparator
    Placebo + valproate or lithium

    Participants randomly received placebo (1:1 to study drug) as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks.

    Drug: Placebo · Drug: Lithium · Drug: Valproate

  • Active comparator
    Aripiprazole + valproate or lithium

    Participants randomly received aripiprazole as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks. Aripiprazole was provided in 5-, 10-, or 15-mg oral tablets and administered at a starting dose of 5 mg per day for Week 1. For Weeks 2 through 3, the dose was titrated up to 10 mg per day, and for Weeks 4 through 6, the dose increased to 15 mg per day. Flexible doses of either 15 or 30 mg per day were administered for Weeks 7 through 12. If participants were unable to tolerate the dose of 15 mg per day of study drug, the dose was decreased to 10 mg per day for Weeks 7 through 12.

    Drug: Aripiprazole · Drug: Lithium · Drug: Valproate

Interventions

  • 5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks

    Also known as: Abilify, BMS-337039

  • DrugPlacebo

    Tablets, Oral, 0 mg, once daily, 12 weeks

  • Participant's ongoing dose

  • DrugValproic AcidStudies of Valproic AcidValproic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participant's ongoing dose

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set)

    The YMRS is a clinician-administered scale, consisting of 11 multiple choice items, and used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-though disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Mania) Scale (LOCF Data Set)

    Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.

    Time frame: Baseline to Weeks 3, 6, 9, and 12

  2. Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Depression) Scale (LOCF Data Set)

    Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.

    Time frame: Baseline to Weeks 3, 6, 9, and 12

  3. Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Overall) Scale at Week 12 (LOCF Data Set)

    Adjusted mean change. The CGI-BP is scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.

    Time frame: Baseline to Week 12

  4. Change From Baseline in Total and Subscale Scores on the Functional Assessment Short Test (FAST)(LOCF Data Set)

    The FAST is an interview-administered instrument used to assess the main functioning problems that patients with bipolar disorder experience. Participants are rated at Baseline, Week 3, Week 6, Week 9, and Week 12/End of Study Visit. The FAST consists of 24 items that assess impairment or disability in 6 specific areas of functioning, categorized as the subscales: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal (IP) relationships, and leisure time. All items are rated using a 4-point scale, 0=no difficulty, 1=mild difficulty, 2=moderate difficulty, and 3=severe difficulty. The global score is the sum of the scores of all items and ranges from 0 (0\*24)to 96 (4\*24). The higher the global score, the higher the level of impairment. function=functioning. LOCF=last observation carried forward.

    Time frame: Baseline to Weeks 3, 6, 9, and 12

  5. Percentage of Participants Showing A Response From Baseline on the Young Mania Rating Scale (YMRS)(OC Data Set)

    Response on the YMRS is defined as a 50% or greater improvement from baseline in YMRS total score. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. OC=observed cases.

    Time frame: Baseline to Weeks 3, 6, 9, and 12

  6. Percentage of Participants Showing Remission in the Young Mania Rating Scale (YMRS) Score From Baseline (LOCF Data Set)

    Remission is defined as a YMRS total score of 12 or less. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.

    Time frame: Baseline to Weeks 3,6, 9, and 12

  7. Change From Baseline in Total Score on the Longitudinal Interval Follow-up Evaluation-Rating Impaired Functioning Tool (LIFE-RIFT)(OC Data Set and Week 12 LOCF Data Set)

    Adjusted mean change. The LIFE-RIFT total score ranges from 4 to 20 and is the sum of scores of 4 items: work, interpersonal relations, satisfaction, and recreation. A negative change score signifies improvement. OC=observed cases; LOCF=last observation carried forward.

    Time frame: Baseline to Weeks 6 and 12

  8. Participant Scores on Patient Global Impression Improvement (PGI-I) Scale (OC Data Set)

    Adjusted Mean Scores. The PGI-I is a self-administered 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. OC=observed cases.

    Time frame: Baseline to Weeks 3, 6, 9, and 12

  9. Change From Baseline in Participant Weight (OC Data Set and Week 12 LOCF Data Set)

    Adjusted mean change.OC=observed cases; LOCF=last observation carried forward.

    Time frame: Baseline to Weeks 3, 6, 9, and 12

  10. Percentage of Participants With Relevant Weight Gain or Weight Loss From Baseline at Week 12 (LOCF Data Set)

    Relevant weight gain=7% or greater increase in weight; relevant weight loss=7% or greater decrease in weight. LOCF=last observation carried forward.

    Time frame: Baseline to Weeks 3, 6, 9, and12

  11. Change From Baseline to Week 12 in Body Mass Index (BMI) (LOCF Data Set)

    BMI=Weight in kilograms /(Height in meters\^2). LOCF=last observation carried forward.

    Time frame: Baseline to Week 12

07

Results

Posted Feb 4, 2013

Participant flow

Participant flow — Overall Study
MilestonePlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Started189181
Completed131122
Not completed5859
Withdrew: Lack of efficacy1110
Withdrew: Adverse event2523
Withdrew: Withdrawal by subject1114
Withdrew: Lost to follow-up35
Withdrew: Poor compliance/noncompliance35
Withdrew: Pregnancy10
Withdrew: No longer meets study criteria01
Withdrew: Other reasons41

Outcome measures

PrimaryChange From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set)

The YMRS is a clinician-administered scale, consisting of 11 multiple choice items, and used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-though disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.

Time frame:
Baseline to Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set)
Units on a scalePlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set)-11.54 ± 0.78-13.57 ± 0.78
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.058 · Mean difference (final values): -2.04 · 95% CI -4.14 to 0.07
SecondaryChange From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Mania) Scale (LOCF Data Set)

Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.

Time frame:
Baseline to Weeks 3, 6, 9, and 12
Reported as:
Mean · Units on a scale
Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Mania) Scale (LOCF Data Set)
Units on a scalePlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Week 3 (n=183, 174)-0.97 ± 0.08-0.93 ± 0.08
Week 6 (n=186, 176)-1.35 ± 0.09-1.46 ± 0.10
Week 9 (n=186, 176)-1.55 ± 0.10-1.83 ± 0.11
Week 12 (n=186, 176)-1.78 ± 0.11-2.07 ± 0.11
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA · p = 0.669 · Mean difference (net): 0.05 · 95% CI -0.16 to 0.25Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA · p = 0.436 · Mean difference (net): -0.10 · 95% CI -0.36 to 0.16Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA · p = 0.053 · Mean difference (net): -0.28 · 95% CI -0.56 to 0.00Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA · p = 0.044 · Mean difference (final values): -0.30 · 95% CI -0.59 to -0.01Week 12
SecondaryChange From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Depression) Scale (LOCF Data Set)

Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.

Time frame:
Baseline to Weeks 3, 6, 9, and 12
Reported as:
Mean · Units on a scale
Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Depression) Scale (LOCF Data Set)
Units on a scalePlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Week 3 (n=183, 174)-0.01 ± 0.05-0.09 ± 0.05
Week 6 (n=186, 176)-0.02 ± 0.06-0.01 ± 0.06
Week 9 (n=186, 176)-0.04 ± 0.070.11 ± 0.07
Week 12 (n=186, 176)-0.03 ± 0.080.14 ± 0.08
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA model · p = 0.240 · Mean difference (net): -0.08 · 95% CI -0.22 to 0.06Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA model · p = 0.843 · Mean difference (net): 0.02 · 95% CI -0.15 to 0.19Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA model · p = 0.117 · Mean difference (net): 0.16 · 95% CI -0.04 to 0.35Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA model · p = 0.109 · Median difference (final values): 0.17 · 95% CI -0.04 to 0.38Week 12
SecondaryChange From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Overall) Scale at Week 12 (LOCF Data Set)

Adjusted mean change. The CGI-BP is scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.

Time frame:
Baseline to Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Overall) Scale at Week 12 (LOCF Data Set)
Units on a scalePlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Overall) Scale at Week 12 (LOCF Data Set)-1.51 ± 0.11-1.59 ± 0.11
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA model · p = 0.567 · Mean difference (final values): -0.08 · 95% CI -0.37 to 0.20Week 12
SecondaryChange From Baseline in Total and Subscale Scores on the Functional Assessment Short Test (FAST)(LOCF Data Set)

The FAST is an interview-administered instrument used to assess the main functioning problems that patients with bipolar disorder experience. Participants are rated at Baseline, Week 3, Week 6, Week 9, and Week 12/End of Study Visit. The FAST consists of 24 items that assess impairment or disability in 6 specific areas of functioning, categorized as the subscales: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal (IP) relationships, and leisure time. All items are rated using a 4-point scale, 0=no difficulty, 1=mild difficulty, 2=moderate difficulty, and 3=severe difficulty. The global score is the sum of the scores of all items and ranges from 0 (0\*24)to 96 (4\*24). The higher the global score, the higher the level of impairment. function=functioning. LOCF=last observation carried forward.

Time frame:
Baseline to Weeks 3, 6, 9, and 12
Reported as:
Mean · Units on a scale
Change From Baseline in Total and Subscale Scores on the Functional Assessment Short Test (FAST)(LOCF Data Set)
Units on a scalePlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Total score: Week 3 (n=179, 169)-5.68 ± 0.86-5.00 ± 0.87
Total score: Week 6 (n=182, 171)-8.59 ± 0.98-6.93 ± 0.99
Total score: Week 9 (n=182, 171)-9.18 ± 1.06-7.71 ± 1.07
Total score: Week 12 (n=182, 171)-10.39 ± 1.09-8.51 ± 1.10
Autonomy score: Week 3 (n=179, 169)-0.93 ± 0.18-0.93 ± 0.18
Autonomy score: Week 6 (n=182, 171)-1.44 ± 0.19-1.11 ± 0.19
Autonomy score: Week 9 (n=182, 171)-1.56 ± 0.21-1.20 ± 0.21
Autonomy score: Week 12 (n=182, 171)-1.84 ± 0.21-1.45 ± 0.21
Occupational function score: Week 3 (n=179, 169)-0.65 ± 0.25-1.00 ± 0.25
Occupational function score: Week 6 (n=182, 171)-1.23 ± 0.29-1.40 ± 0.29
Occupational function score: Week 9 (n=182, 171)-1.20 ± 0.30-1.22 ± 0.30
Occupational function score: Week 12 (n=182, 171)-1.49 ± 0.30-1.24 ± 0.30
Cognitive function score: Week 3 (n=179, 169)-1.33 ± 0.23-0.99 ± 0.23
Cognitive function score: Week 6 (n=182, 171)-2.12 ± 0.26-1.46 ± 0.26
Cognitive function score: Week 9 (n=182, 171)-2.30 ± 0.26-1.68 ± 0.27
Cognitive function score: Week 12 (n=182, 171)-2.59 ± 0.27-1.91 ± 0.28
IP relationships score: Week 3 (n=179,169)-1.57 ± 0.25-1.33 ± 0.26
IP relationships score: Week 6 (n=182, 171)-2.20 ± 0.28-1.91 ± 0.29
IP relationships score: Week 9 (n=182, 171)-2.41 ± 0.31-2.14 ± 0.31
IP relationships score: Week 12 (n=182, 171)-2.57 ± 0.31-2.31 ± 0.31
Leisure time score: Week 3 (n=179, 169)-0.50 ± 0.11-0.28 ± 0.11
Leisure time score: Week 6 (n=182, 171)-0.53 ± 0.13-0.34 ± 0.13
Leisure time score: Week 9 (n=182, 171)-0.52 ± 0.13-0.52 ± 0.13
Leisure time score: Week 12 (n=182, 171)-0.68 ± 0.13-0.59 ± 0.13
Financial issues score: Week 3 (n=179, 169)-0.78 ± 0.12-0.48 ± 0.12
Financial issues score: Week 6 (n=182, 171)-1.16 ± 0.12-0.76 ± 0.13
Financial issues score: Week 9 (n=182, 171)-1.25 ± 0.13-0.99 ± 0.13
Financial issues score: Week 12 (n=182, 171)-1.30 ± 0.12-1.07 ± 0.13
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.566 · Mean difference (final values): 0.68 · 95% CI -1.66 to 3.03Total score: Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.221 · Mean difference (final values): 1.66 · 95% CI -1.00 to 4.32Total score: Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.315 · Mean difference (final values): 1.47 · 95% CI -1.40 to 4.35Total score: Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.212 · Mean difference (final values): 1.88 · 95% CI -1.08 to 4.84Total score: Week 12
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.991 · Mean difference (final values): 0.00 · 95% CI -0.49 to 0.48Autonomy score: Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.201 · Mean difference (final values): 0.34 · 95% CI -0.18 to 0.85Autonomy score: Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.198 · Mean difference (final values): 0.37 · 95% CI -0.19 to 0.93Autonomy score: Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.178 · Mean difference (final values): 0.39 · 95% CI -0.18 to 0.96Autonomy score: Week 12
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.311 · Mean difference (final values): -0.34 · 95% CI -1.01 to 0.32Occupational functioning score: Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.671 · Mean difference (final values): -0.17 · 95% CI -0.94 to 0.61Occupational functioning score: Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.968 · Mean difference (final values): -0.02 · 95% CI -0.83 to 0.79Occupational functioning score: Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.546 · Mean difference (final values): 0.25 · 95% CI -0.56 to 1.07Occupational functioning score: Week 12
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.284 · Mean difference (final values): 0.34 · 95% CI -0.28 to 0.96Cognitive functioning score: Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.063 · Mean difference (final values): 0.66 · 95% CI -0.04 to 1.35Cognitive functioning score: Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.090 · Mean difference (final values): 0.62 · 95% CI -0.10 to 1.34Cognitive functioning score: Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.072 · Mean difference (final values): 0.68 · 95% CI -0.06 to 1.42Cognitive functioning score: Week 12
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.499 · Mean difference (final values): 0.24 · 95% CI -0.45 to 0.93Interpersonal relationships score: Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.457 · Mean difference (final values): 0.29 · 95% CI -0.48 to 1.06Interpersonal relationships score: Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.525 · Mean difference (final values): 0.27 · 95% CI -0.56 to 1.10Interpersonal relationships score: Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.544 · Mean difference (final values): 0.26 · 95% CI -0.58 to 1.09Interpersonal relationships score: Week 12
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.149 · Mean difference (final values): 0.22 · 95% CI -0.08 to 0.52Leisure time score: Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.264 · Mean difference (final values): 0.19 · 95% CI -0.15 to 0.54Leisure time score: Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.988 · Mean difference (final values): 0.00 · 95% CI -0.35 to 0.35Leisure time score: Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.641 · Mean difference (final values): 0.08 · 95% CI -0.27 to 0.44Leisure time score: Week 12
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.068 · Mean difference (final values): 0.29 · 95% CI -0.02 to 0.61Financial issues score: Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.019 · Mean difference (final values): 0.40 · 95% CI 0.07 to 0.74Financial issues score: Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.136 · Mean difference (final values): 0.26 · 95% CI -0.08 to 0.60Financial issues score: Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.18 · Mean difference (final values): 0.23 · 95% CI -0.11 to 0.57Financial issues score: Week 12
SecondaryPercentage of Participants Showing A Response From Baseline on the Young Mania Rating Scale (YMRS)(OC Data Set)

Response on the YMRS is defined as a 50% or greater improvement from baseline in YMRS total score. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. OC=observed cases.

Time frame:
Baseline to Weeks 3, 6, 9, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Showing A Response From Baseline on the Young Mania Rating Scale (YMRS)(OC Data Set)
Percentage of participantsPlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Week 3 (n=183, 174)26.229.3
Week 6 (n=186, 176)46.249.4
Week 9 (n=186, 176)53.864.2
Week 12 (n=186, 176)61.368.8
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · Ration of response · p = 0.466 · Risk ratio (rr): 1.13 · 95% CI 0.81 to 1.59Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · Risk ratio · p = 0.540 · Risk ratio (rr): 1.07 · 95% CI 0.86 to 1.32Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · Risk ratio · p = 0.060 · Risk ratio (rr): 1.17 · 95% CI 0.99 to 1.38Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · Risk ratio · p = 0.289 · Risk ratio (rr): 1.07 · 95% CI 0.94 to 1.23
SecondaryPercentage of Participants Showing Remission in the Young Mania Rating Scale (YMRS) Score From Baseline (LOCF Data Set)

Remission is defined as a YMRS total score of 12 or less. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.

Time frame:
Baseline to Weeks 3,6, 9, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Showing Remission in the Young Mania Rating Scale (YMRS) Score From Baseline (LOCF Data Set)
Percentage of participantsPlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Week 3 (n=183, 174)30.631.0
Week 6 (n=186, 176)48.951.7
Week 9 (n=186, 176)57.065.9
Week 12 (n=186, 176)64.069.9
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · Risk ratio (RR) · p = 0.909 · Risk ratio (rr): 1.02 · 95% CI 0.75 to 1.39Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · RR · p = 0.573 · Risk ratio (rr): 1.06 · 95% CI 0.86 to 1.30Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · RR · p = 0.080 · Risk ratio (rr): 1.16 · 95% CI 0.98 to 1.36Week 9
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · RR · p = 0.211 · Risk ratio (rr): 1.10 · 95% CI 0.95 to 1.27Week 12
SecondaryChange From Baseline in Total Score on the Longitudinal Interval Follow-up Evaluation-Rating Impaired Functioning Tool (LIFE-RIFT)(OC Data Set and Week 12 LOCF Data Set)

Adjusted mean change. The LIFE-RIFT total score ranges from 4 to 20 and is the sum of scores of 4 items: work, interpersonal relations, satisfaction, and recreation. A negative change score signifies improvement. OC=observed cases; LOCF=last observation carried forward.

Time frame:
Baseline to Weeks 6 and 12
Reported as:
Mean · Units on a scale
Change From Baseline in Total Score on the Longitudinal Interval Follow-up Evaluation-Rating Impaired Functioning Tool (LIFE-RIFT)(OC Data Set and Week 12 LOCF Data Set)
Units on a scalePlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Week 6 (n=146, 135)-2.13 ± 0.22-1.45 ± 0.23
Week 12 (n=123, 115)-3.20 ± 0.28-2.37 ± 0.28
Week 12 (LOCF) (n=165, 150)-2.30 ± 0.27-1.69 ± 0.28
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA model · Mean difference (net): 0.68 · 95% CI 0.07 to 1.29Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA model · p = 0.031 · Mean difference (final values): 0.83 · 95% CI 0.08 to 1.58Week 12
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA model · p = 0.104 · Mean difference (final values): 0.61 · 95% CI -0.13 to 1.34Week 12 (LOCF)
SecondaryParticipant Scores on Patient Global Impression Improvement (PGI-I) Scale (OC Data Set)

Adjusted Mean Scores. The PGI-I is a self-administered 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. OC=observed cases.

Time frame:
Baseline to Weeks 3, 6, 9, and 12
Reported as:
Mean · Units on a scale
Participant Scores on Patient Global Impression Improvement (PGI-I) Scale (OC Data Set)
Units on a scalePlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Week 3 (n=178, 168)2.94 ± 0.102.99 ± 0.10
Week 6 (n=151, 140)2.39 ± 0.112.64 ± 0.11
Week 12 (n=127, 119)2.02 ± 0.122.24 ± 0.12
Week 12 (LOCF) (n=181, 173)2.60 ± 0.132.88 ± 0.13
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · Mean difference (net): 0.06 · 95% CI -0.21 to 0.32Week 3
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · Mean difference (net): 0.24 · 95% CI -0.05 to 0.53Week 6
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.197 · Mean difference (final values): 0.21 · 95% CI -0.11 to 0.54Week 12
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.111 · Mean difference (final values): 0.28 · 95% CI -0.07 to 0.63Week 12 (LOCF)
SecondaryChange From Baseline in Participant Weight (OC Data Set and Week 12 LOCF Data Set)

Adjusted mean change.OC=observed cases; LOCF=last observation carried forward.

Time frame:
Baseline to Weeks 3, 6, 9, and 12
Reported as:
Mean · Kilograms
Change From Baseline in Participant Weight (OC Data Set and Week 12 LOCF Data Set)
KilogramsPlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Week 3 (n=177, 171)-0.06 ± 0.160.14 ± 0.15
Week 6 (n=152,144)-0.02 ± 0.200.29 ± 0.21
Week 9 (n=142, 128)0.07 ± 0.26-0.01 ± 0.26
Week 12 (n=133, 123)0.22 ± 0.290.02 ± 0.29
Week 12 (LOCF) (n=183, 174)0.11 ± 0.240.11 ± 0.23
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANOVA/ANCOVA model · p = 0.983 · Mean difference (final values): 0.01 · 95% CI -0.63 to 0.64Week 12 LOCF
SecondaryPercentage of Participants With Relevant Weight Gain or Weight Loss From Baseline at Week 12 (LOCF Data Set)

Relevant weight gain=7% or greater increase in weight; relevant weight loss=7% or greater decrease in weight. LOCF=last observation carried forward.

Time frame:
Baseline to Weeks 3, 6, 9, and12
Reported as:
Number · Percentage of participants
Percentage of Participants With Relevant Weight Gain or Weight Loss From Baseline at Week 12 (LOCF Data Set)
Percentage of participantsPlacebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Weight gain: Week 12 (n=184,174)4.35.2
Weight loss: Week 12 (n=184,174)2.74.0
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · Risk Ratio · Risk ratio (rr): 1.45 · 95% CI 0.57 to 3.71Weight gain
SecondaryChange From Baseline to Week 12 in Body Mass Index (BMI) (LOCF Data Set)

BMI=Weight in kilograms /(Height in meters\^2). LOCF=last observation carried forward.

Time frame:
Baseline to Week 12
Reported as:
Median · kg/m^2
Change From Baseline to Week 12 in Body Mass Index (BMI) (LOCF Data Set)
kg/m^2Placebo + Valproate or LithiumAripiprazole + Valproate or Lithium
Change From Baseline to Week 12 in Body Mass Index (BMI) (LOCF Data Set)0.0 (0.0 to 0.3)0.0 (0.0 to 0.4)
Statistical analysis
  • Placebo + Valproate or Lithium vs Aripiprazole + Valproate or Lithium · ANCOVA · p = 0.582 · Median difference (final values): 0.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole—11/180 (6.1%)45/180 (25%)
Placebo—17/189 (9%)29/189 (15.3%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventAripiprazolePlacebo
ManiaPsychiatric disorders2/1807/189
DepressionPsychiatric disorders4/1802/189
Alcohol abusePsychiatric disorders0/1802/189
HyperthermiaGeneral disorders1/1800/189
ComaNervous system disorders1/1800/189
Psychotic disorderPsychiatric disorders1/1800/189
Vertebrobasilar insufficiencyNervous system disorders1/1800/189
Bipolar I disorderPsychiatric disorders1/1800/189
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/1800/189
Depression suicidalPsychiatric disorders1/1800/189
Most frequent other events
Most frequent other events
EventAripiprazolePlacebo
AkathisiaNervous system disorders20/1804/189
DepressionPsychiatric disorders14/1805/189
InsomniaPsychiatric disorders10/18010/189
NauseaGastrointestinal disorders10/1805/189
HeadacheNervous system disorders5/18010/189

Baseline characteristics

Age Continuous
Age Continuous(Years)Placebo + Valproate or LithiumAripiprazole + Valproate or LithiumTotal
Mean44.92 ± 12.9944.37 ± 12.1344.65 ± 12.57
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Valproate or LithiumAripiprazole + Valproate or LithiumTotal
Female99101200
Male9080170
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo + Valproate or LithiumAripiprazole + Valproate or LithiumTotal
White179172351
Black/African American6612
Asian123
Other314
08

Study locations

73 sites
  • Local Institution
    Salzburg, 5020, Austria
  • Local Institution
    Wien, 1090, Austria
  • Local Institution
    Hradec Kralove, 500 05, Czech Republic
  • Local Institution
    Litomerice, 41201, Czech Republic
  • Local Institution
    Prague 2, 120 00, Czech Republic
  • Local Institution
    Praha 10, 101 00, Czech Republic
  • Local Institution
    Praha, 160 00, Czech Republic
  • Local Institution
    Beaupuy, 31850, France
  • Local Institution
    Brumath Cedex, 67173, France
  • Local Institution
    Chateau Gontier, 53200, France
  • Local Institution
    Clermont-Ferrand Cedex, 63001, France
  • Local Institution
    Dijon, 21000, France
  • Local Institution
    Dole, 39100, France
  • Local Institution
    Jonzac Cedex, 175003, France
  • Local Institution
    Le Vesinet, 78110, France
  • Local Institution
    Montpellier Cedex 5, 34295, France
  • Local Institution
    Nimes, 30900, France
  • Local Institution
    Paris, 75116, France
  • Local Institution
    Reims Cedex, 51092, France
  • Local Institution
    Saint Nazaire Cedex, 44606, France
  • Local Institution
    Sotteville Les Rouen, 76300, France
  • Local Institution
    Strasbourg Cedex, 67091, France
  • Local Institution
    Ellwangen, 73479, Germany
  • Local Institution
    Ostfildern, 73760, Germany
  • Local Institution
    Athens, 151 26, Greece
  • Local Institution
    Leros, 85400, Greece
  • Local Institution
    Nea Ionia-Athens, 14233, Greece
  • Local Institution
    Tripolis, 22100, Greece
  • Local Institution
    Budapest, 1083, Hungary
  • Local Institution
    Budapest, 1097, Hungary
  • Local Institution
    Budapest, 1125, Hungary
  • Local Institution
    Budapest, 1135, Hungary
  • Local Institution
    Gyor, 9024, Hungary
  • Local Institution
    Gyula, 5700, Hungary
  • Local Institution
    Campobasso, 86100, Italy
  • Local Institution
    Foggia, 71100, Italy
  • Local Institution
    Foligno (Pg), 06034, Italy
  • Local Institution
    Genova, 16132, Italy
  • Local Institution
    La Spezia, 19124, Italy
  • Local Institution
    Milano, 20121, Italy
  • Local Institution
    Napoli, 80131, Italy
  • Local Institution
    Pisa, 56126, Italy
  • Local Institution
    Roma, 00168, Italy
  • Local Institution
    Roma, 00189, Italy
  • Local Institution
    Sant'Arsenio (Salerno), 84037, Italy
  • Local Institution
    Choroszcz, 16070, Poland
  • Local Institution
    Gdansk, 80-952, Poland
  • Local Institution
    Krakow, 30-393, Poland
  • Local Institution
    Krakow, 31-501, Poland
  • Local Institution
    Poznan, 60-572, Poland
  • Local Institution
    Swiecie N/Wisla, 86-100, Poland
  • Local Institution
    Bucharest, 041915, Romania
  • Local Institution
    Cluj-Nappoca, 400012, Romania
  • Local Institution
    Iasi, 700282, Romania
  • Local Institution
    Khotkovo, 141371, Russian Federation
  • Local Institution
    Krasnodar, 350087, Russian Federation
  • Local Institution
    Moscow, 115522, Russian Federation
  • Local Institution
    Moscow, 119992, Russian Federation
  • Local Institution
    Rostov-On-Don, 344010, Russian Federation
  • Local Institution
    Samara, 443016, Russian Federation
  • Local Institution
    St.Petersburg, 192019, Russian Federation
  • Local Institution
    Tomsk, 634014, Russian Federation
  • Local Institution
    Johannesburg, Gauteng 2198, South Africa
  • Local Institution
    Soweto, Gauteng 2001, South Africa
  • Local Institution
    Vereeniging, Gauteng 1939, South Africa
  • Local Institution
    Pinetown, Kwa Zulu Natal 3600, South Africa
  • Local Institution
    Cape Town, Western Cape 7530, South Africa
  • Local Institution
    Barcelona, 08036, Spain
  • Local Institution
    Madrid, 28046, Spain
  • Local Institution
    Murcia, 30120, Spain
  • Local Institution
    Ankara, 06100, Turkey
  • Local Institution
    Antalya, 07070, Turkey
  • Local Institution
    Denizli, 20100, Turkey
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2008
First posted
Apr 23, 2008
Start
Jun 2008
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Feb 4, 2013
Last update
Dec 2, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00665366
Responsible party
Sponsor
First posted
Apr 23, 2008
Start date
Jun 2008
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Feb 4, 2013
Last update
Dec 2, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion